Core Viewpoint - MediPharm Labs Corp. has signed a definitive supply agreement with Remidose Aerosols Inc. to ship GMP-certified medicinal cannabis products to Costa Rica, enhancing its commitment to support medical patients in the region and expand international access to quality cannabis solutions [1][2]. Company Overview - MediPharm Labs specializes in precision-based cannabinoids and operates a GMP-certified facility for the development and manufacture of pharmaceutical-quality cannabis products [6]. - The company has a strong focus on research-driven methodologies and advanced technology for producing pure and precision-dosed cannabis products [6]. - In 2021, MediPharm Labs became the only company in North America to hold a commercial-scale domestic GMP License for the extraction of multiple natural cannabinoids [7]. - The acquisition of VIVO Cannabis Inc. in 2023 expanded MediPharm's reach to medical patients in Canada, Australia, and Germany [8]. Market Context - Costa Rica's medical cannabis market opened for regulated sales in June 2025 and is projected to exceed USD 35 million annually, driven by strong patient demand and a comprehensive regulatory framework [2]. - The partnership with Remidose LATAM aims to provide high-quality, GMP-certified cannabis products to meet the needs of patients in Costa Rica [4]. Agreement Details - Under the agreement, MediPharm Labs will supply a variety of GMP-certified cannabis products, including oils, tinctures, metered dose inhalers, and dried flower to Remidose LATAM [3]. - Remidose LATAM is fully licensed by Costa Rican health authorities to import medicinal cannabis products, ensuring compliance with local regulations [4][5].

VANCOUVER, British Columbia, Jan. 09, 2026 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a pharmaceutical manufacturer specializing in cannabis, announces that it has engaged MCS Market Communication Service GmbH (“MCS”) to provide certain marketing and communications services. The engagement is expected to commence on January 12, 2026, and continue for a period of approximately 60 days, or until the allocated budget is exhausted, subject to ear ...

Core Viewpoint - HYTN Innovations Inc. has engaged MCS Market Communication Service GmbH for marketing and communications services to enhance awareness of the company and its business [1][2]. Group 1: Engagement Details - The engagement with MCS is set to begin on January 12, 2026, and will last approximately 60 days or until the budget is exhausted [2]. - MCS will provide services including the review of existing marketing materials, development of digital content, keyword optimization, project coordination, and media distribution [2]. - The total compensation for MCS's services is €50,000, with no securities issued as compensation [3]. Group 2: Company Overview - HYTN Innovations Inc. specializes in the formulation, manufacturing, marketing, and sale of products containing psychoactive and psychotropic compounds, particularly cannabis-derived cannabinoids [4]. - The company focuses on federally regulated markets, applying pharmaceutical-grade development and quality systems [4]. - HYTN aims to identify regulated market opportunities and leverage its integrated development and commercialization platform to advance products to market [4].

Core Viewpoint - The reclassification of cannabis from Schedule I to Schedule III under the U.S. Controlled Substances Act is a significant milestone that recognizes its medical use and is expected to facilitate clinical research and partnerships for MediPharm Labs [1][4][10]. Industry Impact - The reclassification is anticipated to accelerate cannabis-related medical research by removing barriers that have historically limited U.S. clinical trials, allowing for standardized medical-grade cannabis access [4][5]. - The change may lead to increased interest from institutional investors in research-oriented cannabis companies, as regulatory barriers evolve [10]. Company Positioning - MediPharm Labs is strategically positioned to benefit from this reclassification due to its FDA site registration, Drug Establishment License, and experience in supplying clinical trial materials to the U.S. [2][6]. - The company has a proven track record, having supplied products for over 10 active clinical trials, including significant studies funded by the U.S. National Institutes of Health [7][8]. Research and Development Opportunities - The reclassification is expected to create a pipeline of researchers ready to advance clinical trials and evaluate compliant active pharmaceutical ingredient suppliers [5]. - MediPharm Labs has developed international licensing and regulatory expertise, enabling it to support new research initiatives that require pharmaceutical-grade standards [6][9]. Future Growth Potential - The company anticipates that the reclassification will strengthen its ability to expand U.S. clinical trial partnerships and facilitate significant growth in clinical research [3][10]. - MediPharm Labs' unique combination of experience and regulatory credentials positions it to immediately support new research initiatives in the U.S. and globally [8][9].

Core Viewpoint - The announcement of an executive order by the U.S. administration to reclassify cannabis to a Schedule III controlled substance under federal law is a significant development for the cannabis industry, particularly for companies like HYTN Innovations Inc. that are positioned to benefit from a more structured regulatory framework [1][2]. Regulatory Changes - The executive order directs federal agencies to initiate the process of moving cannabis from Schedule I to Schedule III under the U.S. Controlled Substances Act, which would recognize accepted medical use while maintaining regulatory controls [2]. - A Schedule III classification would align cannabis with substances like acetaminophen with codeine and testosterone, allowing for a regulated framework for cannabis as a pharmaceutical product rather than just state-level recreational or medical use [2][3]. Company Positioning - HYTN Innovations Inc. welcomes the executive order, viewing it as a move towards a more structured regulatory approach that aligns with pharmaceutical frameworks. The company has been building systems and infrastructure consistent with Good Manufacturing Practices (GMP) [4]. - The company holds a Health Canada Drug Establishment Licence (DEL) for non-sterile pharmaceutical manufacturing and a Cannabis Drug Licence (CDL), positioning it to manufacture cannabis-derived pharmaceutical products [5][6]. Market Opportunities - HYTN has established a GMP platform and international export operations supplying regulated medical markets in the United Kingdom, Germany, and Australia, which may allow the company to evaluate potential opportunities as the Schedule III regulatory process advances [5]. - The company aims to become a premier provider of cannabis-derived products across federally regulated markets by strategically identifying market opportunities and bringing innovative products to market [6].

Core Viewpoint - MediPharm Labs Corp. has successfully dismissed a defamation claim against its CEO and Chairman, reinforcing its legal standing and credibility in the market [1][2][3]. Legal Developments - The Superior Court of Justice in Ontario dismissed a $50 million defamation claim against CEO David Pidduck and Chairman Chris Taves, which was initiated by Apollo Technology Capital Corporation and Nobul Technologies Inc. [1][3] - The court's decision followed a previous dismissal of a related conflict of interest claim against the company's litigation counsel [2]. - The court found that the plaintiffs failed to provide evidence of harm caused by the April 29 letter, which was deemed typical of legal correspondence in such circumstances [3]. Company Background - MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and active pharmaceutical ingredients, operating under Good Manufacturing Practices [5]. - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, making it the only North American company with a commercial-scale GMP license for extracting multiple natural cannabinoids [6]. - In 2023, MediPharm expanded its market reach by acquiring VIVO Cannabis Inc., enhancing its presence in Canada, Australia, and Germany [7].

Core Viewpoint - MediPharm Labs Corp. is set to release its third quarter financial results for the period ending September 30, 2025, on November 13, 2025, before market opening [1] Group 1: Financial Results Announcement - The company will host a conference call and webcast on November 13, 2025, at 10:00 a.m. Eastern time to discuss its financial results [2] - Participants are encouraged to dial in approximately 15 minutes before the start of the call [3] Group 2: Company Overview - Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates and advanced derivative products [5] - The company operates a Good Manufacturing Practices certified facility with ISO standard-built clean rooms, focusing on delivering pure and precision-dosed cannabis products [5] - In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America with a commercial-scale domestic GMP License for the extraction of multiple natural cannabinoids [6] - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany [7]

Core Viewpoint - RAMM Pharma Corp. is proposing a US$5 million investment in Global South for a 10% equity interest, subject to minority shareholder approval at a special meeting scheduled for November 12, 2025 [1][4]. Transaction Description - The proposed investment values Global South at US$50 million post-investment, with RAMM granted a call option to acquire an additional 15% equity interest, potentially increasing total ownership to 25% at a future valuation of US$400 million [4]. - The transaction is classified as a "related party transaction" under Multilateral Instrument 61-101 due to Global South being wholly owned by the CEO of RAMM, Jackie Peter Burnett, who will be excluded from voting [4]. - The company currently lacks sufficient funds to complete the transaction but plans to monetize assets or obtain financing to raise the necessary capital [4]. - The purchase price for the 10% interest remains fixed at US$5 million, regardless of any changes in Global South's valuation before the transaction's completion [4]. Background of the Transaction - The Special Committee of RAMM's Board was formed to review the transaction, engaging an independent valuator to assess the strategic rationale and financial forecasts of Global South [6][8]. - The Fair Market Value Report concluded that the transaction is fair from a financial perspective for minority shareholders [6][8]. - Global South is developing the GSDC stablecoin, which is pegged to a diversified basket of BRICS+ fiat currencies and backed by real-world assets to mitigate inflationary pressures [8]. Company Overview - RAMM Pharma operates in cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals, with a diversified international production and sales platform [7]. - The company has subsidiaries in Italy and Poland, focusing on extraction, processing, and distribution of hemp products [9].

Company Overview - Vertanical is a Munich-based pharmaceutical company developing a cannabinoid-based extract, Ver-01, aimed at treating chronic pain, with hopes for approval in the EU and the U.S. [1][4] - The founder, Clemens Fischer, has invested over $250 million of his own money into Vertanical since its establishment in 2017 [4][10]. Product Development - Ver-01 has successfully passed Phase III clinical trials in Germany, showing effectiveness greater than opioid painkillers with fewer side effects and no evidence of addiction [4][6]. - The company is awaiting marketing approval from German and Austrian authorities, with plans to apply for broader EU authorization and to launch Phase III trials in the U.S. by 2026 [4][10]. Market Potential - The U.S. cannabis industry is valued at $32 billion in 2024, but the focus for Vertanical is on the pharmaceutical approval process rather than the recreational market [3][6]. - The market for non-opioid pain relievers is significant, with 125 million opioid prescriptions written in the U.S. in 2023, representing a market worth approximately $20 billion annually [6][7]. Competitive Landscape - Vertanical aims to be the first non-opioid chronic pain treatment worldwide, competing with existing alternatives and addressing the urgent need for effective pain management solutions [5][6]. - Other companies, such as the Stanley Brothers, are also developing cannabis-derived drugs, indicating a growing interest in FDA-approved cannabis medicines [8][9]. Financial Projections - If approved, Ver-01 is expected to achieve blockbuster status, with projected revenues exceeding $2 billion within the first two years on the market [11][12]. - The average cost to bring a new drug through the FDA approval process is around $880 million, with a high failure rate, emphasizing the financial risks involved [10][11].

Core Insights - Avicanna Inc. reported Q2 2025 results, highlighting growth in its commercial channels and achieving positive adjusted EBITDA for the first half of 2025, indicating operational efficiency and financial discipline [2][5]. Financial Highlights - Revenue for Q2 2025 was $6.16 million, a 1% increase year-over-year, while revenue for the six-month period was $12.48 million, reflecting a 1% decrease compared to the same period in 2024 [5]. - Gross profit for Q2 was $3.13 million, with a gross margin of 51%, and for the six-month period, gross profit totaled $6.73 million with a margin of 54%, up from 47% in the prior-year periods [5]. - Adjusted EBITDA showed a loss of $0.25 million for Q2 but a gain of $0.18 million for the six-month period, marking an improvement from losses of $0.44 million and $0.42 million in the same periods of 2024 [5]. Corporate Highlights - The company expanded its product offerings, ending Q2 with 50 commercial SKUs and 147 listings, representing a 19% increase in SKUs and a 9% increase in listings from Q1 2025 [5]. - Avicanna sold 50,789 units in Q2, a 21% increase compared to the same period in 2024 [5]. - The company announced a sponsorship for a Phase II clinical study on osteoarthritis pain, which is its first placebo-controlled, blinded randomized multicenter trial [5]. - A symposium on cannabinoid-based medicine was held in June 2025, focusing on research and clinical applications, attended by key opinion leaders and healthcare providers [5]. - Avicanna received a new patent from the US Patent and Trademark Office for a topical cannabinoid composition aimed at treating skin conditions [5][6].